Eduardo Nabais de Carvalho Lauro

Dr. Eduardo Nabais de Carvalho Lauro

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
ELEduardo Nabais de Carvalho Lauro
Eduardo Nabais de Carvalho Lauro
Bruna wenyi Chuang JouBruna wenyi Chuang Jou
Bruna wenyi Chuang Jou
HFHumberto Gomes Ferraz
Humberto Gomes Ferraz
Michele Georges IssaMichele Georges Issa
Michele Georges Issa
Marcelo Dutra DuqueMarcelo Dutra Duque
Marcelo Dutra Duque
The aim of this study was to use the physiologically based biopharmaceutics modeling (PBBM) strategy to evaluate the biopredictive power of different dissolution test conditions for immediate release tablets containing 20 mg of rivaroxaban. The model was developed and validated with literature data and used to predict plasma concentration-time curves of reference drug product Xarelto® 20 mg based on the experimental dissolution profiles. Virtual bioequivalence studies were run considering each dissolution profile under fasted and fed conditions to evaluate the biopredictive power of each dissolution method. The dissolution profiles and the results of the virtual bioequivalence studies showed that it is necessary to have a minimal amount of surfactant (0.15%), rotation speed of at least 60 rpm and 900 mL of acetate buffer solution pH 4.5 to achieve biopredictive condition. Using the PBBM approach, it was possible to evaluate the differences of the dissolution test conditions, and its influence on drug bioavailability, setting up a dissolution specification for rivaroxaban immediate release tablets.